Oxandrolona (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Oxandrolona" in Spanish language version.

refsWebsite

Global rank Spanish rank

15doi.org

2^nd place

14nih.gov

4^th place

9books.google.com

3^rd place

7^th place

6fda.gov

447^th place

668^th place

1drugs.com

399^th place

648^th place

1justice.gc.ca

2,540^th place

5,539^th place

1gov.uk

432^nd place

1,327^th place

1issn.org

57^th place

3^rd place

1archive.org

6^th place

5^th place

1wikimedia.org

low place

archive.org

Fox M, Minot AS, Liddle GW (September 1962). «Oxandrolone: a potent anabolic steroid of novel chemical configuration». The Journal of Clinical Endocrinology and Metabolism 22 (9): 921-924. PMID 13894381. doi:10.1210/jcem-22-9-921.

books.google.com

Anabolics. Molecular Nutrition Llc. 2011. pp. 342-352. ISBN 978-0-9828280-1-4.
Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier. 21 de febrero de 2009. pp. 142-. ISBN 978-0-08-093292-7.
The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 de noviembre de 2014. pp. 911-. ISBN 978-1-4757-2085-3.
Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 767-. ISBN 978-3-88763-075-1.
Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. 6 de diciembre de 2012. pp. 211-. ISBN 978-94-011-4439-1.
World Health Organization (1982). International Nonproprietary Names (INN) for Pharmaceutical Substances: Cumulative List: Dénominations Communes Internationales (DCI) Pour Les Substances Pharmaceutiques: Liste Récapitulative. p. 225. ISBN 978-92-4-056013-0.
William Andrew Publishing (22 de octubre de 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935-. ISBN 978-0-8155-1856-3.
Pocket Guide to Addiction Assessment and Treatment. American Psychiatric Pub. 3 de mayo de 2016. pp. 69-. ISBN 978-1-61537-072-6.
Getting High: The Effects of Drugs. Xlibris Corporation. 26 de febrero de 2013. pp. 39-. ISBN 978-1-4797-9450-8.

doi.org

dx.doi.org

Li H, Guo Y, Yang Z, Roy M, Guo Q (June 2016). «The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis». Burns 42 (4): 717-727. PMID 26454425. doi:10.1016/j.burns.2015.08.023.
Rojas Y, Finnerty CC, Radhakrishnan RS, Herndon DN (December 2012). «Burns: an update on current pharmacotherapy». Expert Opinion on Pharmacotherapy 13 (17): 2485-2494. PMC 3576016. PMID 23121414. doi:10.1517/14656566.2012.738195.
Kicman AT (June 2008). «Pharmacology of anabolic steroids». British Journal of Pharmacology 154 (3): 502-521. PMC 2439524. PMID 18500378. doi:10.1038/bjp.2008.165.
Korkia P, Stimson GV (October 1997). «Indications of prevalence, practice and effects of anabolic steroid use in Great Britain». International Journal of Sports Medicine 18 (7): 557-562. PMID 9414081. doi:10.1055/s-2007-972681. «Low dose 28 +/- 18; High dose 80 +/- 13».
Bork K (August 2012). «Current management options for hereditary angioedema». Current Allergy and Asthma Reports 12 (4): 273-280. PMID 22729959. doi:10.1007/s11882-012-0273-4.
Choi G, Runyon BA (May 2012). «Alcoholic hepatitis: a clinician's guide». Clinics in Liver Disease 16 (2): 371-385. PMID 22541704. doi:10.1016/j.cld.2012.03.015.
Wit JM, Oostdijk W (June 2015). «Novel approaches to short stature therapy». Best Practice & Research. Clinical Endocrinology & Metabolism 29 (3): 353-366. PMID 26051296. doi:10.1016/j.beem.2015.01.003.
Mohamed S, Alkofide H, Adi YA, Amer YS, AlFaleh K (October 2019). «Oxandrolone for growth hormone-treated girls aged up to 18 years with Turner syndrome». The Cochrane Database of Systematic Reviews 2019 (10). PMC 6820693. PMID 31684688. doi:10.1002/14651858.CD010736.pub2.
Sas TC, Gault EJ, Bardsley MZ, Menke LA, Freriks K, Perry RJ, Otten BJ, de Muinck Keizer-Schrama SM, Timmers H, Wit JM, Ross JL, Donaldson MD (2014). «Safety and efficacy of oxandrolone in growth hormone-treated girls with Turner syndrome: evidence from recent studies and recommendations for use». Hormone Research in Paediatrics 81 (5): 289-297. PMID 24776783. doi:10.1159/000358195.
Corona G, Rastrelli G, Vignozzi L, Maggi M (June 2012). «Emerging medication for the treatment of male hypogonadism». Expert Opinion on Emerging Drugs 17 (2): 239-259. PMID 22612692. doi:10.1517/14728214.2012.683411.
Saygin D, Tabib T, Bittar HE, Valenzi E, Sembrat J, Chan SY, Rojas M, Lafyatis R (1991). «Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension». Pulmonary Circulation 10 (1). PMC 7052475. PMID 32166015. doi:10.1515/JPEM.1991.4.4.249.
Orr R, Fiatarone Singh M (2004). «The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety». Drugs 64 (7): 725-750. PMID 15025546. doi:10.2165/00003495-200464070-00004.
«Androgen Receptor». Nuclear Receptors. 2010. pp. 143-182. ISBN 978-90-481-3302-4. doi:10.1007/978-90-481-3303-1_6.
Pappo R, Jung CJ (1962). «2-oxasteroids: A new class of biologically active compounds». Tetrahedron Letters 3 (9): 365-371. ISSN 0040-4039. doi:10.1016/S0040-4039(00)70883-5.
Fox M, Minot AS, Liddle GW (September 1962). «Oxandrolone: a potent anabolic steroid of novel chemical configuration». The Journal of Clinical Endocrinology and Metabolism 22 (9): 921-924. PMID 13894381. doi:10.1210/jcem-22-9-921.

drugs.com

«Oxandrolone».

fda.gov

«Controlled Substances Act». United States Food and Drug Administration. 11 de junio de 2009. Consultado el 17 de junio de 2016.
«Oxandrolone (Oxandrin) use and the interaction with warfarin». U.S. Food and Drug Administration. September 2004. Consultado el 20 de junio de 2016.
«Oxandrin (oxandrolone) Dear Healthcare Professional Letter Apr 2004». Safety Alerts for Human Medical Products. U.S. Food and Drug Administration. 20 de abril de 2004. Consultado el 20 de junio de 2016.

accessdata.fda.gov

«Oxandrolone Tablets, USP - Rx only». Drugs@FDA. U.S. Food and Drug Administration. 1 de diciembre de 2006. Consultado el 21 de junio de 2016.
«Oxandrin (oxandrolone tablets, USP)». Drugs@FDA. BTG Pharmaceuticals, U.S. Food and Drug Administration. 21 de abril de 2003. Consultado el 21 de junio de 2016.
«Drugs@FDA: FDA Approved Drug Products». United States Food and Drug Administration. Consultado el 11 de noviembre de 2017.

gov.uk

«List of most commonly encountered drugs currently controlled under the misuse of drugs legislation - GOV.UK». www.gov.uk. Consultado el 14 de enero de 2017.

issn.org

portal.issn.org

Pappo R, Jung CJ (1962). «2-oxasteroids: A new class of biologically active compounds». Tetrahedron Letters 3 (9): 365-371. ISSN 0040-4039. doi:10.1016/S0040-4039(00)70883-5.

justice.gc.ca

laws-lois.justice.gc.ca

Legislative Services Branch. «Consolidated federal laws of Canada, Controlled Drugs and Substances Act=». laws-lois.justice.gc.ca. Consultado el 14 de enero de 2017.

nih.gov

ncbi.nlm.nih.gov

Li H, Guo Y, Yang Z, Roy M, Guo Q (June 2016). «The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis». Burns 42 (4): 717-727. PMID 26454425. doi:10.1016/j.burns.2015.08.023.
Rojas Y, Finnerty CC, Radhakrishnan RS, Herndon DN (December 2012). «Burns: an update on current pharmacotherapy». Expert Opinion on Pharmacotherapy 13 (17): 2485-2494. PMC 3576016. PMID 23121414. doi:10.1517/14656566.2012.738195.
Kicman AT (June 2008). «Pharmacology of anabolic steroids». British Journal of Pharmacology 154 (3): 502-521. PMC 2439524. PMID 18500378. doi:10.1038/bjp.2008.165.
Korkia P, Stimson GV (October 1997). «Indications of prevalence, practice and effects of anabolic steroid use in Great Britain». International Journal of Sports Medicine 18 (7): 557-562. PMID 9414081. doi:10.1055/s-2007-972681. «Low dose 28 +/- 18; High dose 80 +/- 13».
Bork K (August 2012). «Current management options for hereditary angioedema». Current Allergy and Asthma Reports 12 (4): 273-280. PMID 22729959. doi:10.1007/s11882-012-0273-4.
Choi G, Runyon BA (May 2012). «Alcoholic hepatitis: a clinician's guide». Clinics in Liver Disease 16 (2): 371-385. PMID 22541704. doi:10.1016/j.cld.2012.03.015.
Wit JM, Oostdijk W (June 2015). «Novel approaches to short stature therapy». Best Practice & Research. Clinical Endocrinology & Metabolism 29 (3): 353-366. PMID 26051296. doi:10.1016/j.beem.2015.01.003.
Mohamed S, Alkofide H, Adi YA, Amer YS, AlFaleh K (October 2019). «Oxandrolone for growth hormone-treated girls aged up to 18 years with Turner syndrome». The Cochrane Database of Systematic Reviews 2019 (10). PMC 6820693. PMID 31684688. doi:10.1002/14651858.CD010736.pub2.
Sas TC, Gault EJ, Bardsley MZ, Menke LA, Freriks K, Perry RJ, Otten BJ, de Muinck Keizer-Schrama SM, Timmers H, Wit JM, Ross JL, Donaldson MD (2014). «Safety and efficacy of oxandrolone in growth hormone-treated girls with Turner syndrome: evidence from recent studies and recommendations for use». Hormone Research in Paediatrics 81 (5): 289-297. PMID 24776783. doi:10.1159/000358195.
Corona G, Rastrelli G, Vignozzi L, Maggi M (June 2012). «Emerging medication for the treatment of male hypogonadism». Expert Opinion on Emerging Drugs 17 (2): 239-259. PMID 22612692. doi:10.1517/14728214.2012.683411.
Saygin D, Tabib T, Bittar HE, Valenzi E, Sembrat J, Chan SY, Rojas M, Lafyatis R (1991). «Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension». Pulmonary Circulation 10 (1). PMC 7052475. PMID 32166015. doi:10.1515/JPEM.1991.4.4.249.
Orr R, Fiatarone Singh M (2004). «The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety». Drugs 64 (7): 725-750. PMID 15025546. doi:10.2165/00003495-200464070-00004.
Fox M, Minot AS, Liddle GW (September 1962). «Oxandrolone: a potent anabolic steroid of novel chemical configuration». The Journal of Clinical Endocrinology and Metabolism 22 (9): 921-924. PMID 13894381. doi:10.1210/jcem-22-9-921.

nlm.nih.gov

«Oxandrolone». MedlinePlus. The American Society of Health-System Pharmacists, Inc. 15 de mayo de 2016. Consultado el 21 de junio de 2016.

wikimedia.org

commons.wikimedia.org

Drugs of Abuse. United States Drug Enforcement Administration. 2011. p. 22.